At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 13 enrolled
Drug / intervention
MLN9708drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Open-label, Single-center Phase II Study of MLN9708 (Ixazomib) in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas
In Brief
A Phase 2 clinical trial evaluating MLN9708 for Lymphoma, T-Cell. Completed, enrolled 13 participants across 1 site.
Detailed Summary
Historically cutaneous and peripheral T-cell lymphomas have response rates of approximately 30% to standard chemotherapy regimens. We alternatively hypothesize that MLN9708 will be active in this disease and will improve best objective response. We will also determine the extent to which MLN9708 inhibits GATA-3 (Trans-acting T-cell-specific transcription factor) expression, which is associated with poor prognosis, and whether GATA-3 expression represents a novel predictive biomarker for MLN9708 sensitivity.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma, T-Cell
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJun 2014
Enrollment StartSep 2014
Primary CompletionOct 2016
Study CompletionNov 2016
TodayJul 2026
First PostedJun 9, 2014
Enrollment StartSep 1, 2014
Primary CompletionOct 1, 2016
Study CompletionNov 1, 2016
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 12.1 years ago
Interventions
MLN9708drug